Key result
Neonatal hypertension primarily affects infants with chronic lung or renal disease and typically resolves over time.
This review highlights that while neonatal hypertension is rare and often resolves, there is a significant need for studies on appropriate treatment and long-term prognosis.
Answers are grounded in this paper and cite their sources.
Clinical decisions lack supporting trial data; leaves open needs for studies on treatment thresholds and long-term outcomes.
PURPOSE OF REVIEW: Continued interest in neonatal hypertension has led to generation of new data on normal blood pressure (BP) values in neonates, identification of new causes of hypertension in the neonatal period, and improved insights into therapy. RECENT FINDINGS: Normal BP in neonates depends on a variety of factors, including gestational age, postnatal age, and birth weight, and may be influenced by other antenatal conditions. The incidence of neonatal hypertension is low, and it is most often seen in infants with concurrent conditions such as chronic lung disease (CLD) or renal disease, or in those that have undergone umbilical arterial catheterization. Although few data exist on efficacy and safety of antihypertensive medications in neonates, a wide variety of medications have been utilized in those who do require treatment. Hypertension resolves over time in most infants, although robust long-term outcome data are lacking. SUMMARY: Our understanding of neonatal hypertension continues to evolve. Although better data are available on normal BP and the incidence of hypertension, we still need studies focused on appropriate treatment and long-term prognosis.
No takes yet. Share an insight, caveat, or question.
Joseph T. Flynn (2012) conducted a review in Neonatal hypertension. Neonatal hypertension is a rare condition most often seen in infants with concurrent conditions such as chronic lung disease or renal disease, and it typically resolves over time.
Synapse has enriched 10 related papers. Consider them for comparative context: